

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/579,025
Filing Date	October 19, 2006
First Named Inventor	Panicali
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	701281
DHHS Reference No.	E-087-2005/0-US-03

Sheet	1	of	1
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	A A	WO	01/24832	A2	Gabriele Pecher	Apr. 12, 2001		+
	A B	WO	02/101075	A2	Millennium Pharmaceuticals, Inc.	Dec. 19, 2002		
	A C	WO	03/085087	A2	Aventis Pasteur, Limited and Therion Biologics, Limited	Oct. 16, 2003		
	A D	WO	03/106648	A2	Diadexus, Inc.	Dec. 24, 2003		

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A E	LIGTENBERG et al., "Epidialin, A Carcinoma-Associated Mucin, Is Generated by a Polymorphic Gene Encoding Splice Variants with Alternative Amino Termini," <i>Journal of Biological Chemistry</i> , Vol. 265, No. 10, pp. 5573-5578 (1990).		
	A F	ZRIHAN-LICHT et al., "Characterization and Molecular Cloning of a Novel MUC1 Protein, Devoid of Tandem Repeats, Expressed in Human Breast Cancer Tissue," <i>European Journal of Biochemistry</i> , Vol. 224, no. 2, pp. 787-795 (1994).		
	A G	Search Report for EP 04811370.8, completed April 8, 2008.		

Date Considered

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).